APPLICATION
NDA210933
TYPE
NDA
ORIGINAL APPROVAL
2020-10-26
LATEST ACTION
2020-10-26
ROUTE
OPHTHALMIC
DOSAGE FORM
SUSPENSION/DROPS
MARKETING STATUS
Prescription
Products
EYSUVIS · ReferencePrescription
LOTEPREDNOL ETABONATE 0.25% · SUSPENSION/DROPS · OPHTHALMIC
Approval history
2020-10-26Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · Original · standard — Label ↗AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.